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ABSTRACT 
Rising health care spending is a source of concern in the 
U.S.  With new, high-cost health care technology, paying higher 
prices for the use of new technology without considering cheaper, 
equally effective alternatives leads to inefficient spending.   This 
Note focuses on proton beam therapy (“PBT”) for treatment of 
prostate cancer to explore several causes that contribute to high 
health care spending in the U.S.  In treating prostate cancer, 
PBT has not been shown to be more effective than its cheaper 
alternative, IMRT.  Yet, investors and many states continue to 
encourage its use for prostate cancer.  This Note argues that 
inefficient use of PBT increased because existing standard for 
review of new health care technology and its reimbursement 
often suggest new health care technology will be reimbursed at a 
prime rate.  Hence, private investors fueled the development of 
PBT Centers indiscriminately, expecting a high return on their 
investment.  Then, this Note proposes several ways to encourage 
a more efficient use of PBT.  
INTRODUCTION 
 The term “technology evolution” is used when a new technology 
develops and improves upon an existing technology. 1   When a 
technology evolution imposes much larger costs for medical treatment 
than existing technology, the new technology should be evaluated 
critically to examine its efficacy.  This is difficult in medical technology 
(“medtech”) because clinical trials often take a long time to conduct.  
Often, during the time in which researchers conduct trials to demonstrate 
the efficacy of a new medtech, tension arises between those who want to 
encourage patient access to potentially promising treatment and those 
who want to save costs until efficacy of the new technology is proven.2  
                                                
† Duke University School of Law, J.D. expected, May 2020.  
1 Anthony Zietman et al., Technology Evolution: Is It Survival of the Fittest?, 28 
J. CLINICAL ONCOLOGY 4275, 4275 (2010).   
2 See Richard S. Saver, Note, Reimbursing New Technologies: Why Are the 
Courts Judging Experimental Medicine?, 44 STAN. L. REV. 1095, 1096 (1992).  
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 Proton Beam Therapy (“PBT”), a technology used for treating 
cancer by delivering conformal external beam radiation with positively 
charged atomic particles to a well-defined treatment volume,3 is an apt 
example of a technology evolution.  PBT is currently used to treat a 
variety of cancers, but opinions about the appropriateness of its use for 
different cancers vary wildly.  Agreement on its effectiveness is strongest 
for tumors surrounded by critical structures like the eye, brain, and spinal 
cord, and for solid tumors in children.4  For other types of cancers, such 
as prostate cancer, opinions diverge because currently, there isn’t much 
concrete evidence. 5   Some argue that PBT is more effective than 
intensity-modulated radiation therapy (“IMRT”), which is a widely 
adopted treatment for prostate cancer, because of its improved precision 
of the radiation beams.  However, because PBT is much more costly than 
IMRT, its efficacy should be assessed carefully. 
 This Note examines the current landscape of PBT, its use in 
prostate cancer, and its efficacy as a technological evolution.  Part I 
compares PBT with IMRT.  Part II examines PBT’s rise in use and the 
reasons behind it.  Part III proposes a movement to encourage a more 
efficient development of PBT use, while encouraging a continuance in 
research.   
I. PROTON BEAM THERAPY (PBT) VS. INTENSITY-MODULATED 
RADIATION THERAPY (IMRT) 
 To understand the efficacy of adopting PBT for the treatment of 
prostate cancer, PBT must be compared to the existing alternative for 
treating prostate cancer, IMRT.  IMRT uses a disseminated distribution 
of photon radiation to target tumors.6  Photon beams deposit the greatest 
amount of energy “beneath the patient’s surface with a gradual reduction 
in energy deposition” as photons pass through the target, then exit 
through an exit point.7  Comparatively, PBT uses proton particles and 
                                                
3 AM. SOC’Y FOR RADIATION ONCOLOGY, ASTRO MODEL POLICIES, PROTON 




4 Stephanie Jarosek et al., Proton Beam Radiotherapy in the U.S. Medicare 
Population: Growth in Use Between 2006 and 2009, 10 DATA POINTS 1 (2012).  
5 See infra Part II.  
6  INST. FOR CLINICAL AND ECON. REVIEW, BRACHYTHERAPY & PROTON BEAM 
THERAPY FOR TREATMENT OF CLINICALLY-LOCALIZED, LOW-RISK PROSTATE 
CANCER 36 (2008), https://icer-review.org/wp-content/uploads/2016/02/BT-
PBT_Rpt_Final.pdf [hereinafter ICER].  
7 ASTRO, supra note 3.  
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allows “for the majority of its energy to be deposited over a very narrow 
range of tissue at a depth largely determined by the energy of the proton 
beam.” 8   Because the energy deposition of a proton beam rapidly 
increases over a narrow range at a desired depth to produce an intense 
dose, proton beam deposits relatively less radiation energy when entering 
and exiting the body.9  
IMRT is currently the standard form of radiotherapy for treating 
prostate cancer.10  IMRT was quickly and widely adopted when its 
relative effectiveness to existing treatment was uncertain.11  In 2000, 
IMRT treated less than 1% of localized prostate cancers; by 2008, it 
treated 96% of prostate cancer patients.12  Its quick adoption was based 
on two potential benefits: first, IMRT would deliver higher doses of 
radiation to cancer sites, and second, it would reduce radiation exposure 
to surrounding tissue.13  Despite IMRT’s wide adoption, its superiority 
and cost-effectiveness over the alternative treatment still was being 
studied in 2010.14   
 Similar to the adoption of IMRT, many health care providers 
quickly adopted PBT as a treatment for prostate cancer despite its 
uncertainty.  PBT gained popularity as a prostate cancer treatment based 
on the potential theory that it benefits prostate cancer patients by 
reducing the amount of radiation that surrounding organs receive.15  
                                                
8 Id.   
9 Id. 
10 See James B. Yu et al., Proton Versus Intensity-Modulated Radiotherapy for 
Prostate Cancer: Patterns of Care and Early Toxicity, 105 J. NAT’L CANCER 
INST. 25, 25 (2012).   
11 Bruce L. Jacobs et al., Growth of High-Cost Intensity-Modulated 
Radiotherapy for Prostate Cancer Raises Concern About Overuse, 31 HEALTH 
AFF. 1, 1 (2012).  
12 Ryan Jaslow, IMRT Is Best Radiation for Early Prostate Cancer, Study Finds, 
CBS NEWS (Apr. 18, 2012), https://www.cbsnews.com/news/imrt-is-best-
radiation-for-early-prostate-cancer-study-finds/. 
13 Jacobs et al., supra note 11, at 2.  
14 See generally VARIAN MED. SYS., A REVIEW OF INTENSITY MODULATED 
RADIATION THERAPY (IMRT): A COST EFFECTIVE, PERSONALIZED FORM OF 
RADIATION THERAPY 2–3 (2010), http://www.equiphos.com/wp-
content/uploads/2015/05/IMRT_Clinical_Perspectives.pdf (describing the state 
of clinical trials that compare IMRT and another method of treatment for 
prostate cancer, which was widely adopted before IMRT, and stating that there 
are still studies being conducted to compare the comparative effectiveness of the 
two treatments). 
15 See Nathan C. Sheets et al., Intensity-Modulated Radiation Therapy, Proton 
Therapy, or Conformal Radiation Therapy and Morbidity and Disease Control 
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However, studies have failed to demonstrate that PBT provides better 
outcomes than IMRT for prostate cancer patients.16  A study reviewing 
Medicare records of nearly 55,000 prostate cancer survivors found that 
PBT is associated with small reductions in urinary effects, but only 
within the first six months of treatment.17  After that, researchers found 
no difference in side effects between patients treated with PBT and those 
treated with IMRT.18 
 Some studies actually suggest that PBT may result in more 
toxicity than IMRT because   PBT has greater physical and biological 
uncertainties than IMRT. 19  This means that PBT may be more prone to 
errors related to patient set up, positioning, and organ movement during 
treatment.20  A 2012 study of long-term morbidity found that localized 
prostate cancer patients who received PBT had a higher rate of 
gastrointestinal morbidity than those who received IMRT. 21   The 
researchers found no other significant differences in rates of other 
morbidities between IMRT and PBT.22  
 In addition to uncertainty over its relative efficacy and possible 
toxicity, cost is an issue with PBT.  Despite the lack of evidence of its 
superiority, PBT treatment can cost 48,000 dollars or more, while IMRT 
treatment costs around 20,000 dollars.23  PBT treatment is expensive 
because PBT Centers require a huge capital cost.  Construction of earlier 
PBT Centers, which were the size of a football field with concrete walls 
                                                                                                         
in Localized Prostate Cancer, 307 J. AM. MED. ASS’N 1, 7 (2012) (“[PBT] 
relative to IMRT may reduce the proportion of each surrounding organ that 
receives low doses of radiation . . . .”); ICER, supra note 6, at 36. 
16 See Sheets et al., supra note 15, at 6–7.  
17 Yu et al., supra note 10, at 27.  
18 Id.   
19 Justin E. Bekelman et al., Randomized Trials of Proton Therapy: Why They 
Are at Risk, Proposed Solutions, and Implications for Evaluating Advanced 
Technologies to Diagnose and Treat Cancer, 36 J. CLINICAL ONCOLOGY 2461, 
2461 (2018).  
20 Sheets et al., supra note 15, at 7.  
21 Id.   
22 Id.   
23 Jay Hancock, As Proton Centers Struggle, a Sign of a Health Care Bubble?, 
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up to thirteen feet thick, 24 cost between 120 million and 250 million 
dollars.25 
 Although lack of demonstrable efficiency and cost-effectiveness 
are problems with PBT, there are benefits to allowing further research.  
Prostate cancer is slow-developing.  Complete studies about long-term 
effectiveness of PBT can take decades to develop.  For example, research 
demonstrated IMRT’s effectiveness for prostate cancer treatment years 
after its adoption.  Presently, only a few randomized control trials or 
well-conducted cohort studies comparing PBT to other treatments exist.26  
Although irresponsible spending must be avoided, in order to form an 
informed judgment about PBT use in prostate cancer, researchers must 
be able to continue their research about PBT’s effectiveness in prostate 
cancer treatment.   
II. EXPECTATION OF DEMAND, PROFIT, AND THE RISE OF PBT 
 Use of PBT for prostate cancer accounts for an increasing 
portion of Medicare spending.  PBT use for prostate cancer increased 
drastically since 2006, increasing by 68 percent from 2006 to 2009.27  
From 2010 to 2016, Medicare spending for PBT increased from 47 
million to 115 million dollars.28  Prostate cancer treatment is the most 
common use of PBT and accounts for almost half the spending and 
volume.29   It is also the most expensive.  Average total Medicare 
reimbursements ranged from about 5,000 dollars for ocular tumors to 
                                                
24 Matt Goodman, How a Cyclotron Saves Lives, D MAG. (Oct. 2015), 
https://www.dmagazine.com/publications/d-magazine/2015/october/cyclotron-
cancer-fighting-machine/. 
25 See Ezekiel J. Emanuel and Steven D. Pearson, It Costs More, But Is It Worth 
More?, N.Y. TIMES: OPINIONATOR (Jan. 2, 2012), 
https://opinionator.blogs.nytimes.com/2012/01/02/it-costs-more-but-is-it-worth-
more/ (stating that PBT Centers cost $180 million); Glennda Chui, The Power of 
Proton Therapy, SYMMETRY (Dec. 1, 2008), 
https://www.symmetrymagazine.org/article/december-2008/the-power-of-
proton-therapy (“[PBT Centers] cost in the neighborhood of $120 million to 
$180 million . . . .”); Bonnie Berkowitz & Aaron Steckelberg, How Proton 
Therapy Attacks Cancer, WASH. POST (Mar. 30, 2018), 
https://www.washingtonpost.com/graphics/2018/health/proton-beam-
therapy/?utm_term=.390e8cd25d03 (stating that PBT Centers cost $200 million 
to $250 million).  
26 See Jarosek et al., supra note 4, at 1.  
27 Id. at 2, 8.  
28 MEDICARE PAYMENT ADVISORY COMM’N, MEDICARE COVERAGE POLICY AND 
USE OF LOW-VALUE CARE 294 (June 2018).  
29 Id. at 323.  
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25,000 dollars for prostate cancer.30  This rate of reimbursement is also 
much higher than the rate of reimbursement for IMRT.31   
 PBT Centers are extremely costly and treating a high patient 
volume is the only way to recover construction costs.32  Because prostate 
cancer is one of the most common33 and one of the most generously 
reimbursed cancers, treating prostate cancer patients is one of the ways in 
which PBT Centers can profit.  With over 150,000 new cases diagnosed 
every year,34 even a small percentage of prostate cancer patients seeking 
to use PBT would lead to a large increase in the use of the technology.35  
In fact, statistics suggest that PBT Centers do rely on prostate cancer 
patients to increase their patient volume.  Within the region of referral, 9 
percent of prostate cancer patients received PBT treatment for their 
prostate cancer. 36  For patients outside the region of referral, only 2 
percent of the patients received PBT.37  This shows that PBT Centers are 
looking for ways to doing more procedures.38 
 Investors and hospitals alike investing in PBT Centers relied on 
the assumption that PBT Centers will treat large numbers of prostate 
cancer patients and insurers will generously reimburse that.39  Hospitals 
                                                
30 Jarosek et al., supra note 4, at 5. 
31 See Kilian C. Schiller et al., Protons, Photons, and the Prostate—Is There 
Emerging Evidence in the Ongoing Discussion on Particle Therapy for the 
Treatment of Prostate Cancer?, 6 FRONTIERS IN ONCOLOGY 1, 5 (Jan. 28, 2016), 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4729886/ (stating that 
reimbursement for PBT is almost twice as high as that for IMRT).  
32 See Jenny Gold, Proton Beam Therapy Heats Up Hospital Arms Race, 
KAISER HEALTH NEWS (May 31, 2013), https://khn.org/news/proton-beam-
therapy-washington-dc-health-costs/.  
33 See CTRS. FOR DISEASE CONTROL AND PREVENTION, LEADING CANCER CASES 
AND DEATHS, MALE AND FEMALE, 2016, 
https://gis.cdc.gov/Cancer/USCS/DataViz.html (last visited March 25, 2020) 
(showing that, in 2016, prostate cancer was the second most common cancer to 
develop).  
34 See CTRS. FOR DISEASE CONTROL AND PREVENTION, PROSTATE CANCER 
STATISTICS, https://www.cdc.gov/cancer/prostate/statistics/index.htm (last 
visited May 11, 2019) (see information on main page, then click on “trends”). 
35 Jarosek et al., supra note 4, at 9.  
36 Roxanne Nelson, Uncertainty About Proton-Beam Radiotherapy Lingers, 
MEDSCAPE (Jan. 30, 2013), 
https://www.medscape.com/viewarticle/778466#vp_2.   
37 Id.   
38 See id. (quoting a doctor who states that because PBT Centers have excess 
capacity and high costs, they are looking for ways to do more procedures).  
39 Hancock, supra note 23; Jarosek et al., supra note 4, at 9. 
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built their centers with equity and bank loans, expecting to make profits 
and high returns for equity investors.40  Some hospitals partnered with 
for-profit developers to fund the construction of a PBT Center.41  Under 
the assumption that they would treat a large percentage of prostate cancer 
patients, PBT Centers anticipated treating more than 85 patients per 
day.42  Some Centers, such as the Maryland Proton Therapy Center, 
expected to treat about 70 prostate cancer patients a day.43   
 Then-existing legal and legislative structures surrounding 
reimbursements for health technology revolution supported this 
expectation.  Structurally, Medicare typically reimburses new 
technologies without scrutinizing their cost-effectiveness.  Medicare’s 
decision typically affects reimbursement from private insurers as well, 
because private insurers traditionally follow Medicare’s lead for 
reimbursing for new technology.44  Further, there has been an increase in 
legislatively mandated review processes of medical necessity denials.45  
Some states’ regulations even specifically require insurers to defer to the 
judgment of physicians.46   
In addition, under a theory of breach of contract, insurers face 
potential liability for denying coverage for procedures.47  Traditionally, 
where insurance companies’ policies stated that they do not cover 
“experimental” technology, most courts employed the ambiguities rule, 
stating that “experimental technology” was an ambiguous term and 
interpreting it to favor reimbursement.48  In other cases, courts used the 
                                                
40 See Hancock, supra note 23; David Whelan & Robert Langreth, The $150 
Million Zapper, FORBES (Feb. 26, 2009), 
https://www.forbes.com/forbes/2009/0316/062_150mil_zapper.html#85a9bf820
68f.   
41 See, e.g., Gold, supra note 32 (stating that the Baltimore facility is funded by 
a for-profit developer, Advanced Particle Therapy).  
42 See Hancock, supra note 23. 
43 See Gold, supra note 32 (stating that Maryland Proton Therapy Center 
anticipated treating about 200 patients a day, 35% of which would be prostate 
cancer patients).  
44 See Wendy Netter Epstein, The Health Insurer Nudge, 91 S. CAL. L. REV. 595, 
598, 617–18, 620–22 (2018) (citing Bradley Sawyer & Cynthia Cox, How Does 
Health Spending in the U.S. Compare to Other Countries?, PETERSON-KAISER: 
HEALTH SYSTEM TRACKER (Feb. 13, 2018), 
https://www.healthsystemtracker.org/chart-collection/health-spending-u-s-
compare-countries/#item-start).   
45 See Epstein, supra note 44, at 623.  
46 See id.  
47 See id. at 624–25.  
48 Saver, supra note 2, at 1100.  
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reasonable expectations test: where the insurance policy did not clearly, 
conspicuously and plainly notify the insured that the disputed technology 
would not be covered, courts expanded insurance coverage to include the 
new technology.49  
 To the surprise of many, however, PBT Centers’ profit from 
prostate cancer patients has not lived up to the investors’ expectations, 
and many PBT Centers are struggling recoup their large capital cost.50  In 
2013, several major insurers stopped reimbursing PBT use in treating 
prostate cancer.51  Medicare patients alone have been insufficient to 
recoup the massive capital cost of PBT Centers.52  In 2014, Indiana 
University’s PBT Center became the first facility to close.53  A number 
of other PBT Centers followed, closing their facilities or restructuring in 
bankruptcy courts.54  
 Many PBT Centers are adapting to the changing landscape.  
Some new centers are smaller, with one or two treatment rooms 
compared to four or five.55  Smaller PBT Centers can cost less than 50 
million dollars,56 which lessens the burden on the Centers to recoup its 
capital cost by treating a large volume of patients.  Some Centers are 
adapting by modifying their pricing system: University of Pennsylvania, 
the Mayo Clinic and University of Maryland, for example, have set the 
price of PBT equal to IMRT while researchers continue to examine the 
effectiveness of PBT for prostate cancer.57  Others, such as Northwestern 
Proton Therapy, Provision CARES Cancer Center and the Seattle Cancer 
Alliance, have payment programs for patients where the Center, not the 
patients, takes on the financial risk if PBT is not covered by insurance on 
appeal.58  Other efforts are being conducted to make PBT treatment 
cheaper and more efficient.  Several manufacturers, including Mevion 
Medical Systems, Hitachi, and Varian Medical Systems, are invested in 
                                                
49 Id. at 1102.  
50 Hancock, supra note 23. 
51 Melinda Beck, Big Bets on Proton Therapy Face Uncertain Future, WALL ST. 
J. (May 26, 2015), https://www.wsj.com/articles/big-bets-on-proton-therapy-
face-uncertain-future-1432667393. 
52 Hancock, supra note 23.  
53 Id.   
54 Id.   
55 Hancock, supra note 23; see Beck, supra note 51. 
56 Hancock, supra note 23; see Beck, supra note 51. 
57 Janet Weiner, How to Pay for Proton Therapy in Cancer Clinical Trials, 
PENN LDI BLOG (July 20, 2018), https://ldi.upenn.edu/healthpolicysense/how-
pay-proton-therapy-cancer-clinical-trials.  
58 Berkelman et al., supra note 19, at 2462.  
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building compact PBT systems that cost much less than traditional 
systems.59  Studies are under way to find new ways to make PBT faster, 
more agile, and more compact.60  
 On the other hand, some PBT Centers continue to cast their bets 
on profiting from treating high volume of prostate cancer patients.  As of 
2018, there were 27 PBT units in the U.S. and more than 20 Centers 
under construction or in development.61  A PBT Center that opened in 
Manhattan in 2019 cost 300 million dollars62 and expects to treat around 
1,400 patients annually. 63   Out of those 1400 patients, the Center 
anticipates that 20 percent will be prostate cancer patients.64   
III. PROPOSED METHODS TO CURTAIL EXPECTATIONS 
 The legal and legislative systems should aim to curb 
uncontrolled and inefficient development of new health care technology.  
For starters, they should clearly establish guidelines around 
reimbursement of new health care technology and promote cost-effective 
development.  Further, the federal and state governments should re-
consider federal and state regulations that limit competition of PBT 
Centers.   
A. Federal Government 
 Uniform federal regulation signaling more rigorous 
scrutiny of inefficient, wasteful use of medical technology would 
help control the expectation of profit-seeking parties and to 
mitigate state regulation encouraging inefficient use.  Currently, 
the FDA’s approval of and Medicare’s reimbursement processes 
                                                
59 See Beck, supra note 51.  
60 Researchers Aim to Develop Radiation Therapy with Short Exposure Times, 
STAN. MED. NEWS CTR. (Jan. 9, 2019), http://med.stanford.edu/news/all-
news/2019/01/researchers-aim-to-develop-radiation-therapy-with-short-
exposure.html.  
61 Id.   
62 Charles B. Simone, New York Proton Center Advances Mesothelioma 
Treatment, ASBESTOS.COM (Aug. 30, 2019), 
https://www.asbestos.com/blog/2019/08/30/new-york-proton-center-for-
mesothelioma/.  
63 Melanie Grayce West, New York’s First Proton Therapy Center to Open in 
July, WALL ST. J. (May 16, 2019), https://www.wsj.com/articles/new-yorks-
first-proton-therapy-center-to-open-in-july-11558030007. 
64 Barbara Benson, Meet Harlem’s $238 Million Cancer Killer, CRAIN’S N.Y. 
BUS. (Mar. 20, 2015), 
https://www.crainsnewyork.com/article/20150320/HEALTH_CARE/150329991
/meet-harlem-s-238-million-cancer-killer.  
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for new technology does not identify unnecessary care, tending to 
cover new technologies for procedures without demanding 
demonstrated effectiveness.65  
 The FDA should enforce a more stringent device reviews 
processes of new health technology to assess their safety and 
effectiveness.  During the initial approval process, for many categories of 
health care technology, the FDA does not require randomized studies 
showing its safety or effectiveness for approval. 66   Instead, most 
categories of medical devices are subject to a 510(k) approval process, 
which only require preclinical studies––studies done in laboratory 
settings, unlike clinical studies which involve humans––or that it is 
“substantially equivalent” to an existing, already-approved medical 
device.67  As a result of this lenient approval process, several alarming 
failures have taken place.68  The post-approval studies (PAS), which 
allow the FDA to obtain information about “device safety, effectiveness, 
and/or reliability over long-term use of the device[,]” have not been 
rigorously enforced, either.69   
 The FDA should subject PBT to a higher standard of review to 
ensure its safety and effectiveness.  Since approving PBT for cancer 
treatment in 1988, the FDA has cleared numerous developments in PBT 
units for marketing under the substantial equivalence review standard of 
510(k) without considering cost-effectiveness or effectiveness of the 
technology for certain uses.70  Some leniency in initial FDA approval 
                                                
65 See Epstein, supra note 44, at 622. 
66 See Alan M. Garber, Modernizing Device Regulation, 362 NEW ENG. J. MED. 
1161, 1161–62 (Apr. 1, 2010) (stating that for class I, class II, and some class III 
medical devices, clinical trials to show their safety and efficacy are unnecessary 
for FDA approval); JUDITH A. JOHNSON, CONG. RESEARCH SERV., FDA 
REGULATION OF MEDICAL DEVICES 2–3 (Sept. 14, 2016) (naming recent FDA 
approved medical devices that caused patient injury and death, including metal-
on-metal hip plants, pacemakers, defibrillators). 
67 See JOHNSON, supra note 66, at 19–25 (describing the 510(k) process and 
stating that many types of 510(k) processes are less rigorous than PMA process).  
68 See id. at 2–3 (naming recent FDA approved medical devices that caused 
patient injury and death, including metal-on-metal hip plants, pacemakers, 
defibrillators); Garber, supra note 66, at 1162 (mentioning defibrillators that 
have gone through PMA approval process but caused serious harm to patients by 
failing to discharge or discharging inappropriately).    
69 Id. at 11.  
70 See U.S. FOOD & DRUG ADMIN., 510(K) SUMMARY FOR RADIATION THERAPY 
BEAM-SHAPING APERTURE AND RANGE COMPENSATOR APPROVAL (Oct. 23, 
2012); U.S. FOOD & DRUG ADMIN., 510(K) SUMMARY MEVION S250I 
APPROVAL (Dec. 27, 2017); Hitachi Receives FDA Clearance for Probeat 
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processes is necessary to allow consumers to have quick access to new 
and improved medical devices. 71   However, when the FDA first 
approved PBT, there were minimal studies available about the 
effectiveness of  IMRT and studies had not yet demonstrated that PBT 
may be riskier than IMRT.72  The landscape of research showing PBT’s 
safety and effectiveness compared to IMRT is currently different.73  
Therefore, if the FDA enforced a more stringent PAS and re-reviewed 
the safety and effectiveness of PBT in comparison to IMRT, it may lead 
to a re-consideration about whether PBT should continue to be used 
without restrictions for treating prostate cancer.74  
 Medicare’s reimbursement procedures present a similar issue.  
“Medicare performs no evaluation of the benefits associated with new 
medical technologies, and in its fee-for-service incarnation does not ask 
if care could be better managed.”75  Medicare is also very slow to update 
its coverage decisions.76  Hence, Medicare tends to discourage cost-
saving innovation and efficient insurance coverage denials.77  
 In 2017, American Society for Radiation Oncology (ASTRO) 
proposed a policy for PBT.  The ASTRO model suggests that until 
further findings demonstrate its safety and effectiveness, the use of PBT 
for prostate cancer should only be reimbursed when it is used as a part of 
a clinical trial furthering research.78  This strikes the balance between 
discouraging uncontrolled, irresponsible and profit-seeking development 
PBT and allowing reimbursement for the use of PBT where it is apt and 
helpful for further research.  Several private insurers have since adopted 
this model. 79   So far, however, Centers for Medicare & Medicaid 
                                                                                                         
Proton Beam Therapy System, HITACHI (Mar. 21, 2006), 
http://www.hitachi.us/press/03212006 (stating that as one of three PBT Centers 
that are hospital-based in the U.S. at the time, it received FDA approval under 
substantial equivalence standard). 
71 JOHNSON, supra note 66, at 2.  
72 See supra notes 15–16 and accompanying text. 
73 See supra Part I.   
74 See Garber, supra note 66, at 1163.  
75 Baicker et al., Saving Money or Just Saving Lives?  Improving the 
Productivity of US Health Care Spending, 4 ANN. REV. ECON. 33, 40–41 (Apr. 5, 
2012).  
76 Epstein, supra note 44, at 622.  
77 Baicker et al., supra note 75, at 41.  
78 ASTRO Updates Insurance Coverage Recommendations for Proton Therapy, 
AM . SOC’Y FOR RADIATION ONCOLOGY (July 12, 2017), 
https://www.astro.org/News-and-Publications/News-and-Media-Center/News-
Releases/2017/ASTRO-updates-insurance-coverage-recommendations-f. 
79 AM . SOC’Y FOR RADIATION ONCOLOGY supra note 3, at 4. 
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Services (CMS) has not released a national coverage determination for 
PBT, leaving reimbursement decisions up to Local Medicare 
Administrative Contractors (LCDs).80   
 Instead of relying on state Medicare decisions, the national CMS 
should state that use of PBT in prostate cancer will only be reimbursed 
when it is a part of a clinical trial until further findings demonstrate its 
safety and effectiveness.  A clear guidance from the national CMS could 
encourage an exercise of prudence from those seeking to invest in, or 
develop, PBT Centers expecting to quickly recoup the high investment.  
At the least, it could encourage PBT Centers to develop on a smaller and 
cheaper scale or seek funding from non-profit entities so they can focus 
on patient care and research rather than profit.  Decreased pressure from 
investors to recoup the costs would allow PBT Centers to be more 
flexible with the use and price of PBT.  For instance, the Mayo Clinic 
built its PBT Center financed by a 100-million-dollar donation rather 
than relying on private equity.81  The lack of pressure from investors 
allows the Mayo Clinic to charge the same rates for PBT as for IMRT.82 
 Further, the federal government should preempt state regulations 
which retard the movement towards efficient use of PBT.  For example, 
some state bills discourage private insurers from declining coverage of 
PBT treatment for prostate cancer for lack of evidence demonstrating 
effectiveness.83  In 2015, Oklahoma’s bill prohibited health benefit plans 
from “holding [PBT] to a higher standard of clinical evidence for 
medical policy benefit coverage decisions than the health plan requires 
for coverage of any other radiation therapy treatment.”84  Senator Marian 
Cooksey, the author of the bill, stated that insurance companies’ decision 
to not reimburse PBT because of its lack of long-term studies is a “very 
                                                
80 Jarosek et al., supra note 4, at 2; see e.g., FALLON HEALTH, PROTON BEAM 
THERAPY CLINICAL COVERAGE CRITERIA 2 (Apr. 1, 2018), 
https://www.fchp.org/en/providers/criteria-policies-guidelines/medical-
policies.aspx (click on Proton Beam Therapy to download) (stating that 
coverage for Medicare based plans is in accordance with Medicare Local 
Coverage Determination).  
81 See Beck, supra note 51. 
82 See id. 
83 Cf. Daniel Siegal, Aetna Owes $26M Over Denied Cancer Treatment, Jury 
Says, LAW360 (Nov. 8, 2018), https://www.law.com/2018/11/14/25-6m-okla-
verdict-against-aetna-in-denied-treatment-case-raises-bad-faith-
issues/?slreturn=20190022132147 (finding the insurance company to be in bad 
faith for repeatedly refusing to cover PBT for a patient’s tumor in her throat and 
awarding nearly $25.6 million in damages including punitive damages).  
84 See H.B. 1515, 2015 Leg., 1st Sess. (Okla. 2015).  
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weak argument.”85  Oklahoma law, in turn, “ensur[es] that the physician 
has the final say in the treatment, not the insurance company.”86   
 Another example of an inefficient state regulation is State 
Certificate of Need (CON) law, which regulates medtech.  State CON 
laws require health care providers to obtain a permit from the state before 
offering new services, constructing new buildings, or purchasing new 
medical equipment. 87   Once upon a time, the federal government 
supported CON laws and considered them to be cost-containment 
mechanisms.88   But, over time, CON laws were found to have the 
opposite effect.  When states enacted CON laws, their Medicare 
spending increased by 6.9 percent because the CON laws restricted the 
supply of health care.89  When repealed, state health care spending 
decreased by .8 percent per year, leveling out at 4 percent after five years. 
90  The federal government has spoken out against state CON laws.91  
The FTC stated that CON laws “create barriers to expansion, limit[s] 
consumer choice, and stifle[s] innovation.”92   
 Despite the statistics, 35 states and the District of Columbia 
continue to enforce CON laws for at least some health care services.93  
Some states specifically proposed regulation to limit the number of PBT 
Centers in the state.94  Even if state CON laws are not aimed specifically 
                                                
85 New Law Will Protect Proton Therapy Coverage, OK HOUSE, 
https://www.okhouse.gov/Media/ShowStory.aspx?MediaNewsID=5045 (last 
visited Sept. 22, 2019). 
86 Id. 
87 Emily Whelan Parento, Certificate of Need in the Post-Affordable Care Act 
Era, 105 KY. L.J. 201, 205 (2017).  
88 See id. at 205, 207 (stating that the federal government first perceived CON 
laws to be cost-containing mechanisms and required states to enact CON laws 
for a brief period in 1970s and 1980s).   
89 James Bailey, Can Health Spending Be Reined in Through Supply Constraints? 
An Evaluation of Certificate-of-Need Laws, MERCATUS CTR. (Aug. 1, 2016), 
https://www.mercatus.org/publication/health-spending-reined-in-CON-laws. 
90 Id. 
91 See Parento, supra 87, at 215 (stating that the federal government has not been 
neutral towards CON laws and that both the FTC and DOJ have spoken out 
against it).   
92 Agencies Submit Joint Statement Regarding Virginia Certificate-of-Need 
Laws for Health Care Facilities, FEDERAL TRADE COMM’N (Oct. 26, 2015), 
https://www.ftc.gov/news-events/press-releases/2015/10/agencies-submit-joint-
statement-regarding-virginia-certificate. 
93 Parento, supra note 87.  
94 Jay Greene, Local Proton Beam Planners March On: McLaren Rivals Say 
Need Supports Multiple Centers, CRAIN’S DETROIT BUS., (Sept. 29, 2009), 
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to control PBT Centers, operation of PBT facilities often does not pass 
regulatory muster without approved CON.95  
 The FTC should enforce antitrust laws against states that adopted 
CON laws where they are violative of federal antitrust laws.  Requiring 
PBT units to obtain a CON before operating in a state harms consumers 
by “creat[ing] market power” and “limit[ing] patient choice” and 
“creat[ing] opportunities for existing competitors to thwart or delay new 
competition.”96  Under CON law, once a state allows the development of 
one PBT Center, other PBT Centers face extremely high barriers to enter 
the market.97  This effectively tells the PBT Centers that once they 
establish a large Center in a state and becomes approved under CON law, 
they are not likely to have competition.  This can have negative effects 
on cancer patients because this limits patient choice and excludes 
cheaper, or more superior, alternatives that a competitive market may 
offer.98   
 Additionally, with little room to enter the market, new actors 
lack incentive to find cheaper methods of entry.99  Higher barriers of 
entry into the market therefore impede efforts to improve the efficiency 
                                                                                                         
https://www.crainsdetroit.com/article/20090929/EMAIL01/309299993/local-
proton-beam-planners-march-on-mclaren-rivals-say-need (stating that in 2008, 
Michigan Certificate of Need Commission approved regulation to limit the 
number of PBT Centers to a single collaborative of five hospitals).  
95 See Memorandum regarding Proton Beam Therapy from Thomas Jung, Acting 
Director of the Division of Heath Facility Planning of New York to Members of 
the State Hospital Review and Planning Council (Mar. 11, 2010), 
https://www.health.ny.gov/facilities/cons/proton_beam_therapy_demonstration_
project/docs/memorandum.pdf (addressing the question whether operating a 
PBT facility requires CON approval and concluding that it’s difficult, if not 
impossible, to imagine a PBT facility that would pass regulatory muster without 
CON approval).   
96 See, e.g., U.S. DEP’T OF JUSTICE, ANTITRUST DIV., COMMENTS ON PROPOSED 
CERTIFICATE OF NEED STANDARDS FOR PROTON BEAM THERAPY SERVICES, 
https://www.justice.gov/atr/comments-proposed-certificate-need-standards-
proton-beam-therapy-services (June 6, 2008). 
97 See id.(stating that the proposed CON law allows for only one PBT Center to 
operate, and in addition, the approved entities may set terms and standards of 
operation for other seeking to enter the market, and existing entities may thwart 
or delay new competition).  
98 See id.(“[CON] law regimes, by their nature, limit competitive entry and 
impede the proper functioning of the market process.  They can create market 
power where it may not otherwise exist, limit patient choice, and create 
opportunities for existing competitors to thwart or delay new competition”).  
99 See id. 
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or cost of PBT.  In a 2014 report, Ernst & Young (EY) compared the 
medtech market to the personal computer industry in the 90s, arguing 
that low barriers to market entry for the personal computer industry 
encouraged and accelerated the development of the market.100  Lowering 
barriers to market entry in the PBT market is likely to promote 
development of already existing efforts101 to make PBT units faster, 
cheaper, and more efficient by encouraging “reverse innovation”––
finding ways to produce relatively inexpensive, stripped-down versions 
of the units––and encouraging international manufacturers to seek to 
enter the U.S. market as well.102 
The presence of CON law affects the behavior of existing 
PBT Centers and their interaction with potential patients as well.  
With the rising health care costs in the U.S. continuing to be a 
looming issue, the medical health technology field is shifting its 
focus.  Hospitals are increasingly shifting simple cost-cutting to 
increasing value,103 and health care purchasers are prioritizing 
devices that reduce the total cost of care.104  “Payers and providers 
are most interested in highly differentiated medtech products that 
represent a significant improvement over the standard of care.” 105  
PBT, without further research on its effectiveness or the value of 
its technology transfer from IMRT, is more likely to be scrutinized 
under this focus.  Increasing competition is likely to encourage 
PBT Centers to find ways to cut costs and find ways to make PBT 







                                                
100 ERNST & YOUNG, PULSE OF THE INDUSTRY: MEDICAL TECHNOLOGY REPORT 
9 (2014). 
101 See supra notes 59 and 60 and accompanying text.  
102 See generally ERNST & YOUNG, supra note 100. 
103 See id. at 6.  
104 Id. at 8.  
105 Id.  
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B. Insurance Companies 
 Private insurers have been playing a key role in curbing PBT 
reimbursement. In defiance of their traditional ways, insurance 
companies have declined to reimburse PBT treatment of prostate 
cancer.106   In 2013, three major insurers––Regence, Blue Shield of 
California, and Aetna––changed their policies to stop covering PBT for 
prostate cancer, stating that PBT is more costly but without demonstrated 
increased benefits compared to IMRT. 107   Currently, nearly all 
commercial insurers and state Medicaid plans do not cover PBT for 
prostate cancer.108  
 Several recent court decisions have supported the insurance 
companies’ decisions to deny coverage for the use of PBT in prostate 
cancer.  In Baxter v. MBA Group Ins. Trust Health and Welfare Plan,109 
the plaintiff patient brought a claim for wrongful denial of coverage 
against his insurance after being denied reimbursement for PBT for early 
state prostate cancer.  His insurance plan stated that PBT was not 
“medically necessary” as stated by their medical policy because it has 
not been shown to be superior to other approaches.110  Finding that the 
burden of proof was on the plaintiff to establish medical necessity, the 
effectiveness of PBT, and the cost of PBT, the court granted the 
insurance company’s motion for summary judgment.111 
 Similarly, in Woodruff v. Blue Cross and Blue Shield of 
Alabama,112 the plaintiff claimed that Blue Cross Blue Shield (BCBS) 
wrongfully denied his claim for reimbursement of PBT treatment for his 
prostate cancer.  The court granted BCBS’s motion for summary 
judgment, concluding that the court’s role was only to decide whether 
BCBS’s judgment was “reasonable.”113   There, the court found that 
BCBS’s decision to deny coverage was reasonable based on the lack of 
randomized, published studies showing that it is superior to its 
                                                
106 Ron Winslow & Timothy W. Martin, Prostate-Cancer Therapy Comes 
Under Attack, WALL ST. J. (Aug. 28, 2013), 
https://www.wsj.com/articles/prostatecancer-therapy-comes-under-attack-
1377734990?tesla=y; Jaimy Lee, As a Proton Therapy Center Closes, Some See 
It as a Sign, MODERN HEALTHCARE (Sept. 18, 2014), 
https://www.modernhealthcare.com/article/20140918/NEWS/309189939.  
107 See Winslow & Martin, supra note 106.  
108 Bekelman et al., supra note 19.  
109 958 F. Supp. 2d 1223 (W.D. Wash. 2013).  
110 Id. at 1225.  
111 Id. at 1230–38.  
112 2018 WL 571933 (N.D. Ala. Jan. 26, 2018). 
113 Id. at *7.  
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alternatives.114  The court further found that the opinions of a treating 
physician were not “entitled to a presumption of deference.”115   In 
Howard v. Blue Cross and Blue Shield of Arizona,116 too, the district 
court upheld the insurer defendant’s denial of PBT use in prostate cancer, 
finding that the insurer defendant was not “clearly erroneous” in finding 
that PBT use in the plaintiff’s case was not “medically necessary.”  
 In all three cases, courts refer specifically to the language in the 
insurance plan.  In Woodruff and Howard, the insurer defendants clearly 
stated that “medically necessary” encompasses considerations of cost.117  
The Woodruff and Howard insurer defendants further stated in their 
policy that under their “medically necessary” definition, PBT for prostate 
cancer was not covered.118  
 Because insurance policies are read as contracts, where the 
definition of “medically necessary” is clearly stated to include cost-
effectiveness, or PBT is specifically listed in the plan as a non-medically 
necessary treatment based on existing evidence, courts may be less likely 
to inject their own patient-friendly, broad definitions of “medical 
necessity.”  Therefore, until there are sufficient studies on PBT use for 
localized prostate cancer that support its cost compared to that of IMRT, 
courts may continue to rule in the insurer’s favor if the insurance plan 
includes the right language.  This may help curb PBT Centers’ reckless 
                                                
114 Id. at *10.  
115 Id. at *8.  
116 Howard v. Blue Cross Blue Shield of Ariz., No. CV-16-03769-PHX-JJT, 
2019 U.S. Dist. LEXIS 116058 (D. Ariz. July 12, 2019). 
117 See Woodruff, 2018 WL 571933, at *6 (“If a service or supply is not 
addressed . . . it will be considered to be medically necessary only if . . . it is 
appropriate and necessary . . . and performed in the least costly setting, method, 
or manner, or with the least costly supplies required by [the patient’s] medical 
condition.”); Baxter v. MBA Grp. Ins. Tr. Health and Welfare Plan, 958 F. Supp. 
2d 1223, 1228–29 (W.D. Wash. 2013) (“[I]n accordance with generally accepted 
standards of medical practice; clinically appropriate . . . ; not more costly than 
an alternative service or sequence of services or supply at least as likely to 
produce equivalent therapeutic or diagnostic results . . . .”).   
118 See Woodruff, 2018 WL 571933, at *6 (“[PBT] does not meet [BCBS’s] 
medical criteria for coverage in patients with clinically localized prostate cancer, 
because the clinical outcomes with this treatment have not been shown to be 
superior to other approaches including [IMRT] yet proton beam therapy is 
generally more costly . . . .”); Howard, 2019 U.S. Dist. LEXIS 116058, at *9 
(“[PBT] is considered not medically necessarily for clinically localized prostate 
cancer based upon insufficient evidence to support improvement of the net 
health outcome, and insufficient evidence to support improvement of the net 
health outcome as much as, or more than, established alternatives.”).  
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use of PBT for prostate cancer without substantiating its safety or 
effectiveness.   
 At the same time, a complete ban on coverage of PBT use by 
private insurers is likely premature.  One of the problems with PBT is 
that there are no randomized trials showing its effectiveness.  But, 
conducting randomized trials is difficult if there are not enough patients 
to participate in the trials.119  Lack of reimbursements for PBT can result 
in lack of enrollment of patients in clinical trials that may provide 
concrete answers about the long-term effectiveness of PBT.  Coverage 
from Medicare helps, but the number of patients who can participate 
would be significantly limited. 120   Additionally, Medicare includes 
mostly patients over 65, which may reduce the generalizability of the 
results.121  
 To deal with this dilemma, some insurers cover PBT for selected 
cancers being studied to support clinical trials.122  For example, Cigna, 
Independence Blue Cross, and Blue Cross Blue Shield of Florida cover 
PBT for selected cancers under study or have established coverage with 
study participation policies.123  This practice curbs irresponsible use of 
PBT treatment but allows clinical trials to continue their research on 
PBT’s effectiveness and safety.  In the past, continued use of IMRT, 
despite its lack of demonstrated effectiveness, allowed clinical trials to 
continue their studies, which ultimately proved IMRT to be an effective 
method of treatment for prostate cancer.  Such results would have been 
close to impossible had patients been unable to afford IMRT.  Therefore, 
rather than implement a total ban on reimbursement of PBT, private 
insurers should consider the policy of reimbursing those participating in 
clinical trials.  
CONCLUSION 
 Uncontrolled and unregulated health care spending on new 
technology without adequate findings of its effectiveness takes away 
funds that could be spent efficiently elsewhere.  PBT demonstrates 
promise for various types of cancers, but so far, for localized prostate 
cancer, there is a significant lack of research showing its effectiveness 
compared to its alternatives.  
                                                
119 Weiner, supra note 57.  
120 Why Randomized Trials for Proton Therapy are Difficult to Complete (and 
What We Can Do About It), SCI. DAILY (July 11, 2018), 
https://www.sciencedaily.com/releases/2018/07/180711141353.htm.  
121 Id.  
122 Weiner, supra note 57. 
123 Bekelman et al., supra note 19.  
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 The U.S. has seen a rise in the number of PBT Centers and the 
use of PBT, mainly driven by the anticipated profit stemming from the 
its use for treatment of prostate cancer.  This expectation was likely 
fostered by the existing environment facilitating generous reimbursement 
for new medical technology.  Despite the recent financial problems that 
existing PBT Centers have experienced, many PBT Centers continue to 
build, still anticipating high patient volume from prostate cancer patients.  
Curtailing the expectation of demand and profit by establishing a level of 
scrutiny towards inefficient use of PBT on a federal level is likely to 
encourage a more efficient growth of the PBT market.   
